Northgate Biopharma Advisory
Strategic advisory for US and international biopharmaceutical companies seeking successful, sustainable market entry and commercialization across Canada's uniquely complex healthcare environment.
Schedule a Discovery CallThe Canadian Market
Canada is not the US. It is not an EU member country. Organizations that approach Canada with assumptions built elsewhere often discover this too late — launching with a burdened P&L, giving away too much drug too early, struggling with reimbursement, and ultimately pulling back from a market that deserved better planning. These are the five realities that define success or failure.
US and international organizations often assume Canada mirrors their home market. This misread routinely leads to unsustainable launches, access failures, and difficult outcomes for patients who needed those therapies — with lasting impact on future pipeline plans.
Canada's system is a layered mosaic: federal (CDA-AMC, INESSS), pan-provincial (pCPA), provincial, robust private payer market, buying groups and institutional accounts — all requiring distinct strategies. CDA (formerly CADTH / pCODR) & INESSS health technology assessments shape access across public plans and must be strategically navigated early.
Canada's vast geography demands focused, access-driven resourcing. Payer contracts, population densities, healthcare infrastructure, and reimbursement timing vary dramatically by province. Strategic sequencing — knowing where to play and when — is critical to sustainable P&L outcomes.
In specialty, rare disease, and oncology, a Patient Support Program is not optional — it is a launch prerequisite. A negative patient experience in a competitive market is difficult to recover from; a positive one is a powerful differentiator. Knowing what to build, when, and where to invest makes the difference.
Medical affairs and market access must be integrated into P&L planning long before launch. Moving too early or too late through each access "gate" can make a brand non-viable or meaningfully attenuate growth. Timing is everything. Getting it right delivers a sustainable P&L, strong payback period, and earlier breakeven — turning Canada into the asset it should be.
What We Offer
From pre-launch strategy through commercialization, Northgate provides the insight and execution support your Canadian affiliate needs to succeed.
Senior commercial leadership without the full-time overhead. Embedded strategic and operational guidance for your Canadian affiliate at every stage of the lifecycle.
Rigorous assessment of the Canadian access landscape, revenue potential, and organizational requirements — so your entry is built on real knowledge, not assumptions.
End-to-end strategy across federal, CDA-AMC/pan-provincial, provincial, private, and institutional channels — including HTA engagement, specialty and rare disease access planning, and oncology submissions.
Building the full commercial architecture for launch: access pathway design, patient journey mapping, resource build-out, and P&L modeling aligned to Canadian realities.
Forecast modeling grounded in Canadian access timelines, payer demographics, and lifecycle realities — giving leadership the visibility needed for confident investment decisions.
Strategic sequencing of market expansion across provinces — knowing where to play first, when to scale, and how to optimize investment relative to access progress and population opportunity.
Defining PSP requirements, strategy, and design parameters that serve patients and satisfy access requirements — ensuring the right investment in the right places before build begins.
Beyond Strategy
Twenty-five years of leading commercial teams, navigating complex organizations, and making high-stakes decisions creates a particular kind of perspective — one that translates directly into coaching that is grounded, practical, and honest.
Who it's for
Emerging and established biopharma leaders navigating organizational complexity, cross-functional alignment, and high-stakes commercial decisions in the Canadian market.
What it looks like
One-on-one engagements built around your specific situation — not a framework, not a program. Direct, candid, and focused on outcomes that matter to you and your organization.
How We Work
Every engagement begins with honest discovery — understanding your asset, your organization, and your ambitions. From there, we build a plan grounded in the Canadian realities that matter most.
A focused engagement to assess your asset's access landscape, competitive position, patient journey, and organizational readiness. We identify the gaps and the opportunities — with no false comfort about the challenges ahead.
Translating landscape insights into a clear, integrated market access and commercial strategy — including payer sequencing, CDA/CADTH engagement planning, provincial prioritization, PSP requirements, and P&L parameters.
Strategic support through launch and beyond: building teams, managing access negotiations, course-correcting on P&L performance, and ensuring every investment decision is tied to a clear access and commercial outcome.
Canada is a market with a full lifecycle — from launch through loss of exclusivity. Northgate helps organizations navigate each phase with disciplined investment reallocation, contract renegotiation, and sustained commercial performance.
The Advisor
Brent Serson brings a combination of credentials and operational depth that is genuinely uncommon at the senior level in Canadian biopharma: full P&L commercial leadership across franchises and sales forces, market access expertise, a CPA, CA financial designation, Chief of Staff experience at the VP/GM level, and active board governance - including serving as Board Chair.
His commercial leadership spans the full product lifecycle. He has managed marketing and sales force strategy across products at every stage - specialty and rare disease pre-launch planning, launch execution, growth optimization, loss of exclusivity, and biosimilar defence. That breadth of lifecycle experience gives him a practical command of Canadian commercial strategy that is difficult to replicate.
His market access experience is similarly end-to-end. He has worked at the HTA level - helping shape evidence strategy and submission thinking for CDA-AMC review, taking part in pCPA negotiations, leading private payer strategy and contract negotiations, key account and pharmacy strategy, and patient access program design. He understands not just the mechanics of each stage, but how decisions made early in the access pathway affect execution years later at the provincial, private and patient level.
Over 20 years at Amgen Canada and Janssen, Brent has operated at the intersection of commercial strategy and organizational leadership. His time as Chief of Staff to a VP/GM gave him a complete view of how a successful Canadian affiliate is run - the resource allocation decisions, the relationship between local execution and global expectations, and the commercial judgment required to build a sustainable business in a market that rarely receives the attention it deserves from headquarters.
His CPA, CA designation is not incidental. It shapes how he approaches investment cases, affiliate P&L, and the financial rigour that global teams require when assessing Canadian market potential. It is a combination - financial discipline embedded in senior commercial leadership - that very few Canadian biopharma operators can offer.
Brent founded Northgate BioPharma Advisory to bring this experience directly to international specialty and rare disease companies navigating Canadian market entry - without the overhead of firms that haven't operated inside the Canadian system.
View Full Profile on LinkedInGet In Touch
The right conversation about Canada can change the trajectory of your asset. Reach out to explore whether there's a fit.
Northgate Biopharma Advisory works with a select number of clients at a time, ensuring the depth of focus each engagement deserves.
📞 416.725.9016
📍 Mississauga, Ontario, Canada